428 avsnitt

Offering a front row seat to the Century of Biology, veteran podcast host Theral Timpson interviews the who's who in genomics and genomic medicine.

www.mendelspod.com

Mendelspod Podcast Theral Timpson

    • Vetenskap

Offering a front row seat to the Century of Biology, veteran podcast host Theral Timpson interviews the who's who in genomics and genomic medicine.

www.mendelspod.com

    Synthetic Biology in 2024 with John Cumbers

    Synthetic Biology in 2024 with John Cumbers

    John Cumbers is back on the show to preview the annual SynBioBeta, the leading global conference for the synthetic biology crowd. This year’s show includes 18 tracks on AI, space, longevity, and DNA synthesis. Speakers will include Stephen Wolfram and Stephen Quake, who will discuss large language models and biology.
    While 2024 saw a total investment of over $6 billion (not as high as the pandemic year of 2021), John says the new technologies and startups keep coming.
    "We’re seeing just a ton of new entrepreneurs coming out of graduate and undergraduate programs and starting companies.”
    John is the founder and CEO of SynBioBeta which takes place May 6-9th in the San Jose Convention Center.


    This is a public episode. If you’d like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe

    • 25 min
    Illumina Scales Variant Calling and Genome Interpretation to Improve Gap in Genetic Testing with Sam Strom

    Illumina Scales Variant Calling and Genome Interpretation to Improve Gap in Genetic Testing with Sam Strom

    Most of the news coming from Illumina has had to do with their leadership in the sequencing instrument space. What is lesser known is that they offer an end-to-end solution for the clinical lab, including variant calling and genome interpretation.In this podcast, we’re joined by Sam Strom, Principal Scientist at Illumina and a certified Clinical Lab Director.  Sam comes to Illumina from the clinical testing side; for example, he’s co-chair for the expert curation panel for Parkinson’s Disease and sits on a working group at ClinGen.In the interview, Sam addresses two of the big challenges in clinical sequencing, which are variant calling and variant interpretation. Sam says Illumina has created its own multi-sample genomic reference and is also making use of artificial intelligence to improve variant calling. He also shares how Illumina supports scaling variant interpretation for genomes and other assays with an AI and automation comprehensive solution, enabling high-quality genetic testing workflows to reach next level accessibility.“I think we’re going to see more “lights out” testing where there really isn’t an interpretation component to the test.   It’s a pure technical test.  It has certain limitations.  But it gets you 99.9% of the way there.  The technology is ready."


    This is a public episode. If you’d like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe

    • 30 min
    The Renaissance in DNA Synthesis Continues: Cosimo Ducani, CEO, Moligo

    The Renaissance in DNA Synthesis Continues: Cosimo Ducani, CEO, Moligo

    This is a free preview of a paid episode. To hear more, visit www.mendelspod.com

    Today, we feature a new DNA synthesis company out of Sweden that is making a name with long, single-stranded DNA at scale. How long? Over 10,000 bases. Why single-stranded vs. genes? And what is meant by scale?According to Cosimo Ducani, CEO and co-founder of Moligo Technologies, the business of making DNA is just getting started.  So much for thinking it was a mature business in the early 2000s when Integrated DNA Technologies (IDT) dominated the market.

    • 5 min
    Jennifer Wipf of Ginkgo Bioworks on RNA Therapeutics and Cell Therapy

    Jennifer Wipf of Ginkgo Bioworks on RNA Therapeutics and Cell Therapy

    The rise of RNA therapeutics and cell therapies promises to take us where we’ve never been in medicine.  The growing understanding of RNA, mRNA, and circular RNA and their crucial roles in disease has led to their application in targeting previously “undruggable” targets.  Meanwhile, new cell therapies are promising cures to diseases that have plagued us without mercy.  Scientists now ask what can’t we do.  Still, biology remains dauntingly complex.At the base of these fields is a revolution in biological engineering. One company stands out with the impressive vision of making engineering biology easier: Boston-based Ginkgo Bioworks. This past month, Ginkgo announced that it was buying three companies to boost its AI footprint in diagnostics and therapeutics. We think of burgers and perfumes, but Ginkgo’s customer base is impressively diverse. Today, we talk with Jennifer Wipf, Head of Commercial Cell Engineering at Ginkgo. Jennifer says FNA is giving drug developers “access to the cell” which is opening up a whole new approach to therapeutics.    How does Ginkgo help out?  What are the promises and challenges?We end with a question about Ginkgo’s new acquisitions to beef up its AI capabilities after last year's partnership with Google.“If  you want to make biology easier to engineer, we need a way to answer some of these questions without doing a lot of lab work."



    This is a public episode. If you’d like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe

    • 22 min
    Precision Medicine for Dogs: Christina Lopes, OneHealth

    Precision Medicine for Dogs: Christina Lopes, OneHealth

    This is a free preview of a paid episode. To hear more, visit www.mendelspod.com

    Chapters:
    0:00 Number one unmet medical need for dogs
    6:25 Using “extra label” for cross species
    12:57 Ideal for understanding human cancers
    21:25 Playing catch-up with human medicine
    28:04 1,000 pet clinic customers
    Precision medicine for dogs?— as in tumor profiling for the right therapies to treat man’s best friends at the right time? Yes, that’s right. …

    • 5 min
    Taking Gene Therapy to the Next Level: Rahul Kakkar of Tome

    Taking Gene Therapy to the Next Level: Rahul Kakkar of Tome

    There’s a new genome editing company that everyone is talking about this year.  Tome Biosciences came out of stealth in December, claiming the ability to insert DNA sequences of any size at any location across in vivo and ex vivo modalities. Their website says they’re “taking us into the final chapter of medicine.”Tome’s CEO, Rahul Kakkar, joins us today on the program.  He’s a physician-scientist (cardiology) who has previously led a couple of biotech companies, Pandion Therapeutics and Corvidia Therapeutics, through initial funding and acquisition.  Rahul says that even though we’ve seen incredible breakthroughs in the gene therapy arena, all of the current editing technologies are “profoundly limited.”  That includes the technology for the first CRISPR-based drug approval, Casgevy.“Gene therapy today is putting a gene into a cell that has no relationship to the genome itself.  It’s quite unrefined.  From a clinical perspective, their impact is limited because their technology is limited.”Why so limited, and what is this great advancement in editing technology that everyone is talking about?  Rahul says the tech is able to “reprogram” a cell.What are the history and current state of the company and this new technology?  How are they dealing with the infamous “off-target effects?”  And what is the overall opportunity?Rahul talks in grand terms.  He says there is a need for genomic-based therapies if we’re going to move medicine away from treating to curing disease.  



    This is a public episode. If you’d like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe

    • 40 min

Mest populära poddar inom Vetenskap

P3 Dystopia
Sveriges Radio
Dumma Människor
Acast - Lina Thomsgård och Björn Hedensjö
A-kursen
Emma Frans och Clara Wallin
I hjärnan på Louise Epstein
Sveriges Radio
Vetenskapsradion Historia
Sveriges Radio
Sidenote by AsapSCIENCE
AsapSCIENCE

Du kanske också gillar

The Readout Loud
STAT
Raising Health
Andreessen Horowitz
Science Magazine Podcast
Science Magazine
On the Media
WNYC Studios
Consider This from NPR
NPR
Science Friday
Science Friday and WNYC Studios